GlassScriptPhysician profile
James T Williams
NPI 1841630274
$14,592.09
in general payments reported to CMS, 2019-2025
30 companies · $3,508 in 2025
The $3,508 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $98.22 · 2021: $517 · 2022: $363 · 2023: $591 · 2024: $8,716 · 2025: $3,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $10K · Food and Beverage: $1,409 · Travel and Lodging: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,000.00 |
| Food and Beverage | $1,409.27 |
| Travel and Lodging | $1,405.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,520.69 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $608.48 | 2019-2025 | Airsupra, Fasenra, Evusheld |
| Abbvie INC. | $281.58 | 2021-2025 | Avycaz, Teflaro |
| Boston Scientific Corporation | $231.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.42 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $212.95 | 2019-2023 | Uptravi |
| Mallinckrodt Hospital Products INC. | $192.82 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $154.13 | 2022-2023 | Dupixent |
| Mallinckrodt Enterprises LLC | $113.07 | 2019 | |
| Astellas Pharma US INC | $105.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.53 | 2023-2024 | Glassia |
| Pfizer INC. | $96.14 | 2021 | |
| Inari Medical, INC. | $93.23 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| United Therapeutics Corporation | $79.26 | 2019-2025 | Tyvaso |
| Pulmonx Corporation | $72.04 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60.25 | 2021-2023 | |
| Abiomed | $57.35 | 2024 | Impella |
| Insmed, INC. | $54.72 | 2022-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $51.92 | 2022-2023 | Zerbaxa |
| Chiesi USA, INC. | $40.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.20 | 2023-2024 | Xarelto |
| Tetraphase Pharmaceuticals, INC. | $29.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $25.93 | 2025 | Purified Cortrophin Gel |
| Cordis US Corp. | $24.70 | 2025 | Mynx Control |
| Vapotherm INC | $23.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.03 | 2021 | |
| Glaxosmithkline, LLC. | $19.01 | 2022 | |
| La Jolla Pharmaceutical Company | $13.99 | 2020 | |
| Allergan, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.